TGA / PMDA / NMPA · Asia-Pacific
solvent — TGA / PMDA / NMPA regulatory status
solvent regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 84 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 042011 | Phase 3 | George Institute for | 2024-512676-36-00 |
| 0600-PG-PSC-218 | Phase 3 | Anaxis Pharma | 2025-521736-10-00 |
| 060018-PG-PSC-217 | Phase 3 | Anaxis Pharma | 2025-521709-42-00 |
| 071102 | Phase 3 | Baxalta Innovations | 2023-509769-18-00 |
| 111-302 | Phase 3 | BioMarin Pharmaceutical Australia | 2023-508864-31-00 |
| 111-303 | Phase 3 | BioMarin Pharmaceutical Australia | 2024-513129-22-00 |
| 111-308 | Phase 3 | BioMarin Pharmaceutical Australia | 2024-517238-16-00 |
| 2019/2894 | Phase 3 | George Institute for | 2024-514917-36-00 |
| 333-301 | Phase 3 | BioMarin Pharmaceutical Australia | 2025-523811-12-00 |
| A011-14 | Phase 3 | Anaxis Pharma | 2023-509140-10-00 |
| ALL2820 | Phase 3 | Telethon Foundation | 2023-508968-30-00 |
| APHP191099 | Phase 3 | PARItec | 2023-508071-36-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12318376 | Compositions of a polyorthoester and an aprotic solvent | US |
| 11964003 | Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same | US |
| 11957736 | Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same | US |
| 11576951 | Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same | US |
| 11452674 | Non-solvent dental adhesive composition | US |
| 11253504 | Compositions of a polyorthoester and an aprotic solvent | US |
| 10485850 | Methods for producing stable therapeutic formulations in aprotic polar solvents | US |
| 10420720 | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief | US |
| 10398686 | Compositions of a polyorthoester and an aprotic solvent | US |
| 9913909 | Compositions of a polyorthoester and an aprotic solvent | US |
| 9744163 | Compositions of a polyorthoester and an aprotic solvent | US |
| 9675544 | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of solvent?
solvent currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get solvent regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to solvent?
This spoke lists 84 published programs associated with solvent in our pipeline index.